OraSure Technologies (NASDAQ:OSUR) Stock Price Down 6.9%

OraSure Technologies, Inc. (NASDAQ:OSUR) was down 6.9% during trading on Monday . The company traded as low as $10.93 and last traded at $10.97. Approximately 13,279 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 946,407 shares. The stock had previously closed at $11.78.

A number of research analysts have commented on OSUR shares. Lake Street Capital decreased their price objective on OraSure Technologies from $20.00 to $15.00 and set a “buy” rating on the stock in a report on Wednesday, August 4th. Citigroup upped their price objective on OraSure Technologies from $13.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, August 4th. Raymond James increased their target price on OraSure Technologies from $11.00 to $12.50 and gave the stock an “outperform” rating in a report on Wednesday, August 4th. Finally, Zacks Investment Research lowered OraSure Technologies from a “hold” rating to a “sell” rating in a report on Wednesday, August 4th.

The firm has a market capitalization of $769.06 million, a P/E ratio of 152.57 and a beta of -0.28. The firm has a 50-day moving average of $10.89 and a two-hundred day moving average of $10.35.

OraSure Technologies (NASDAQ:OSUR) last announced its quarterly earnings data on Tuesday, August 3rd. The medical instruments supplier reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.06). OraSure Technologies had a return on equity of 1.33% and a net margin of 2.34%. The business had revenue of $57.61 million for the quarter, compared to the consensus estimate of $56.50 million. On average, research analysts predict that OraSure Technologies, Inc. will post 0.09 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in OSUR. BlackRock Inc. lifted its position in shares of OraSure Technologies by 18.4% during the 2nd quarter. BlackRock Inc. now owns 14,054,164 shares of the medical instruments supplier’s stock worth $142,510,000 after buying an additional 2,180,891 shares during the last quarter. Earnest Partners LLC increased its stake in shares of OraSure Technologies by 20.9% in the first quarter. Earnest Partners LLC now owns 3,671,405 shares of the medical instruments supplier’s stock valued at $42,845,000 after buying an additional 634,826 shares during the period. Neuberger Berman Group LLC grew its stake in OraSure Technologies by 46.3% during the first quarter. Neuberger Berman Group LLC now owns 1,972,508 shares of the medical instruments supplier’s stock worth $22,909,000 after purchasing an additional 624,524 shares during the period. Prudential Financial Inc. grew its stake in OraSure Technologies by 112.6% in the first quarter. Prudential Financial Inc. now owns 948,943 shares of the medical instruments supplier’s stock valued at $11,074,000 after acquiring an additional 502,663 shares during the period. Finally, Systematic Financial Management LP lifted its holdings in shares of OraSure Technologies by 28.9% in the second quarter. Systematic Financial Management LP now owns 1,811,603 shares of the medical instruments supplier’s stock valued at $18,370,000 after purchasing an additional 406,661 shares in the last quarter. Institutional investors and hedge funds own 88.63% of the company’s stock.

About OraSure Technologies (NASDAQ:OSUR)

OraSure Technologies, Inc engages in the development, manufacture, and distribution of point of care diagnostic tests and molecular collection devices designed to detect or diagnose critical medical conditions. It operates through the OSUR and DNAG segments. The OSUR segment offer oral fluid diagnostic products and specimen collection devices.

See Also: How does new data get added to a blockchain?

Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.